Real-World Management of Macular Edema Secondary to Retinal Vein Occlusion with Intravitreal Aflibercept: 24-month Results from the AURIGA Observational Study

Giocanti-Aurégan, AudreyAudreyGiocanti-AuréganDonati, SimoneSimoneDonatiHoerauf, HansHansHoeraufAllmeier, HelmutHelmutAllmeierRittenhouse, Kay DKay DRittenhouseMachewitz, TobiasTobiasMachewitzCHANG-HAO YANG2024-01-182024-01-182024-012193-8245https://scholars.lib.ntu.edu.tw/handle/123456789/638611AURIGA is the largest real-world study to date to evaluate intravitreal aflibercept (IVT-AFL) treatment of diabetic macular edema or macular edema secondary to retinal vein occlusion (RVO) in routine clinical practice. Here, we report the 24-month outcomes in the RVO cohort from France, Germany, Italy, and Taiwan.enAnti-vascular endothelial growth factor; Branch retinal vein occlusion; Central retinal vein occlusion; Intravitreal aflibercept; Macular edema; Observational study; Optical coherence tomography; Real-world evidence; Retinal disease; Retinal vein occlusion[SDGs]SDG3Real-World Management of Macular Edema Secondary to Retinal Vein Occlusion with Intravitreal Aflibercept: 24-month Results from the AURIGA Observational Studyjournal article10.1007/s40123-023-00830-w379244812-s2.0-85175639776https://api.elsevier.com/content/abstract/scopus_id/85175639776